LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway

Published:2017-09-21 Issue:54 Volume:8 Page:91990-92003
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhu Qiong-Ni¹,Wang Guo¹,Guo Ying¹,Peng Yan¹,Zhang Rui¹,Deng Jun-Li¹,Li Zhi-Xing¹,Zhu Yuan-Shan¹²

Affiliation:

1. Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Central South University, Changsha, P. R. China

2. Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges;Non-coding RNA Research;2024-12

2. lncRNAs: New players of cancer drug resistance via targeting ABC transporters;IUBMB Life;2024-08

3. Role of LncRNA H19 in tumor progression and treatment;Molecular and Cellular Probes;2024-06

4. Non‐coding RNAs and their potential exploitation in cancer therapy‐related cardiotoxicity;British Journal of Pharmacology;2024-05-27

5. All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells;BMC Cancer;2024-05-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP